直肠癌多线治疗1例个案报道并文献复习
A Case Report and Literature Review of a Case of Multilineage Therapy for Rectal Cancer
摘要: 目的:分析1例晚期直肠癌患者的多程治疗方案,为临床医师对该病的晚期多线治疗的临床实践提供一定的思路。方法:临床医师通过查阅直肠癌相关临床实践指南和文献,结合患者实际病情,制定个体化的诊疗方案。结果:医师通过最新最权威的指南及诊疗规范,确保晚期直肠癌患者治疗的安全、有效,多次延长患者生存。结论:晚期直肠癌三线后尚无标准治疗,治疗方案的临床决策应全盘考虑患者的意愿、身体和经济因素等,结合当下的临床实验,灵活地进行个体化治疗。
Abstract: Objective: To analyze the multi-route treatment plan of a case of advanced rectal cancer, and to provide clinicians with some ideas for the clinical practice of advanced multi-route treatment of this disease. Methods: Clinicians reviewed the relevant clinical practice guidelines and literature on rectal cancer, combined with the actual condition of the patient, and formulated an individualized treatment plan. Results: Clinicians can ensure the safe and effective treatment of advanced rectal cancer patients through the latest and most authoritative guidelines and diagnostic and therapeutic standards, and prolong the survival of patients for many times. Conclusion: There is no standard treatment for advanced rectal cancer after the third line, and the treatment plan should be formulated by comprehensively considering the patients’ wishes, physical and economic factors, etc., and combining with the current clinical experiments, and flexibly carrying out individualized treatment.
文章引用:刘家妮, 赵淑芬, 吕静, 王艳, 董晨, 邱文生. 直肠癌多线治疗1例个案报道并文献复习[J]. 临床医学进展, 2024, 14(4): 1589-1593. https://doi.org/10.12677/acm.2024.1441195

参考文献

[1] Zheng, R.S., Chen, R., Han, B.F., et al. (2024) Cancer Incidence and Mortality in China, 2022. Chinese Journal of Oncology, 46, 221-231.
[2] Matsui, Y., Hamada, M., Matsumi, Y., et al. (2022) Curative Resection of Ureteral Metastasis of Rectal Cancer: A Case Report and Review of Literature. Clinical Journal of Gastroenterology, 15, 151-156. [Google Scholar] [CrossRef] [PubMed]
[3] Siegel, R.L., Miller, K.D. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, No. 1. [Google Scholar] [CrossRef] [PubMed]
[4] Siegel, R.L., Miller, K.D., Sauer, A.G., et al. (2020) Colorectal Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 145-164. [Google Scholar] [CrossRef] [PubMed]
[5] 中华人民共和国国家卫生和计划生育委员会. 直肠癌规范化诊疗指南(试行) [J]. 中国医学前沿杂志(电子版), 2013(7): 56-61.
[6] Fukuoka, S., Hara, H., Takahashi, N., Kojima, T. and Shitara, K. (2020) Regorafenib Plus Nivolumab in Patients with Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). Journal of Clinical Oncology, 38, JCO.19.03296. [Google Scholar] [CrossRef
[7] Kuboki, Y., et al. (2017) TAS-102 plus Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (C-TASK FORCE): An Investigator-Initiated, Open-Label, Single-Arm, Multicentre, Phase 1/2 Study. The Lancet Oncology, 18, 1172-1181. [Google Scholar] [CrossRef
[8] Per, P., Mette, Y., Sören, M., et al. (2020) TAS-102 with or without Bevacizumab in Patients with Chemorefractory Metastatic Colorectal Cancer: An Investigator-Initiated, Open-Label, Randomised, Phase 2 Trial. The Lancet Oncology, 21, 412-420.
[9] 张泽群, 龙飞, 胡桂, 李小荣. 2021年V2版NCCN结肠癌临床实践指南更新解读[J]. 临床外科杂志, 2022, 30(1): 16-19.
[10] 姚宏伟, 刘荫华. NCCN结直肠癌临床实践指南2011年更新解读[J]. 中华胃肠外科杂志, 2011, 14(4): 5.
[11] Qi, C., Gong, J., Li, J., et al. (2022) Claudin18.2-Specific CAR T Cells in Gastrointestinal Cancers: Phase 1 Trial Interim Results. Nature Medicine, 28, 1189-1198. [Google Scholar] [CrossRef] [PubMed]
[12] Almåsbak, H., Aarvak, T. and Vemuri, M.C. (2016) CAR T Cell Therapy: A Game Changer in Cancer Treatment. Journal of Immunology Research, 2016, Article 5474602. [Google Scholar] [CrossRef] [PubMed]